

Special Issue

Kidney Disease: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

This Special Issue “Kidney Disease: From Pathophysiology to Novel Therapeutic Approaches” invites contributions both of original articles and reviews dedicated to improving the knowledge on kidney disorders, focusing on topics such as pathophysiology, renal pathology, biomarkers of renal disorders and novel therapeutic approaches and can include not only the spectrum of glomerular disorders, but also genetic disorders, tubulopathies, diabetic nephropathy and renal transplantation. Renal disorders have an increasing contribution to the global health burden, while end-stage kidney disease is among the leading causes of death worldwide. Tremendous advances have been achieved in recent decades regarding the understanding of the pathophysiology of kidney disorders, having been translated into improved outcomes of patients with chronic kidney disease and the development of novel therapies. Nevertheless, there are still many areas of uncertainty requiring addressing, with this Special Issue’s objective being to approach several of these issues.

Guest Editor

Prof. Dr. Gener Ismail

1. Department of Nephrology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Department of Nephrology, Fundeni Clinical Institute, 022328 Bucharest, Romania

Deadline for manuscript submissions

closed (31 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/105569

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).